Allergists' opinions on anaphylaxis and epinephrine administration—a case-based survey

Jay A. Lieberman; Phil Lieberman; Julie Wang

doi:10.1016/j.jaip.2017.11.031

Allergists' opinions on anaphylaxis and epinephrine administration—a case-based survey

Jay A. Lieberman, Phil Lieberman, Julie Wang

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Original language	English
Pages (from-to)	1075-1077.e1
Journal	Journal of Allergy and Clinical Immunology: In Practice
Volume	6
Issue number	3
DOIs	https://doi.org/10.1016/j.jaip.2017.11.031
State	Published - 1 May 2018
Externally published	Yes

Access to Document

10.1016/j.jaip.2017.11.031

Cite this

@article{f9c32cac7d974a58b997a05e65abdad6,

title = "Allergists' opinions on anaphylaxis and epinephrine administration—a case-based survey",

author = "Lieberman, {Jay A.} and Phil Lieberman and Julie Wang",

note = "Funding Information: Conflicts of interest: J. A. Lieberman receives research support from Aimmune Therapeutics; and has served on the advisory board for Aimmune Therapeutics. P. Lieberman has received a speaking honorarium from Kaleo Pharma; and has served on advisory board for Mylan and Meda Pharmaceuticals. J. Wang receives research support via grants to her institution (from National Institute of Allergy and Infectious Diseases, Aimmune, DBV Technologies); has received consulting fees from Aimmune and DBV Technologies; and receives royalties from UpToDate. ",

year = "2018",

month = may,

day = "1",

doi = "10.1016/j.jaip.2017.11.031",

language = "English",

volume = "6",

pages = "1075--1077.e1",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "American Academy of Allergy, Asthma and Immunology",

number = "3",

}

TY - JOUR

T1 - Allergists' opinions on anaphylaxis and epinephrine administration—a case-based survey

AU - Lieberman, Jay A.

AU - Lieberman, Phil

AU - Wang, Julie

N1 - Funding Information: Conflicts of interest: J. A. Lieberman receives research support from Aimmune Therapeutics; and has served on the advisory board for Aimmune Therapeutics. P. Lieberman has received a speaking honorarium from Kaleo Pharma; and has served on advisory board for Mylan and Meda Pharmaceuticals. J. Wang receives research support via grants to her institution (from National Institute of Allergy and Infectious Diseases, Aimmune, DBV Technologies); has received consulting fees from Aimmune and DBV Technologies; and receives royalties from UpToDate.

PY - 2018/5/1

Y1 - 2018/5/1

UR - http://www.scopus.com/inward/record.url?scp=85039896660&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2017.11.031

DO - 10.1016/j.jaip.2017.11.031

M3 - Article

C2 - 29306683

AN - SCOPUS:85039896660

SN - 2213-2198

VL - 6

SP - 1075-1077.e1

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 3

ER -